Explore All 336 Growth Capital Medical Products Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | January 5, 2018 |
| Target | HCmed |
| Sector | Medical Products |
| Investor(s) | Vivo Capital |
| Deal Type | Growth Capital |
FILTER BY
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 5.3B USD |
| Size | Mega |
| Type | Sector Focused |
Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1996 and is headquartered in Palo Alto, California.
| Deal Context for Investor | # |
|---|---|
| Overall | 16 of 29 |
| Sector: Medical Products | 6 of 10 |
| Type: Growth Capital | 2 of 5 |
| Country: Taiwan | 2 of 2 |
| Year: 2018 | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-11-27 |
Medeor Therapeutics
San Mateo, California, United States Medeor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients. Medeor Therapeutics was founded in 2012 and is based in San Mateo, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-01-29 |
VYNE Therapeutics
Bridgewater, New Jersey, United States VYNE Therapeutics is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough. VYNE Therapeutics was founded in 2003 and is based in Bridgewater, New Jersey. |
Sell | - |
